BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28742685)

  • 21. Radiation dose does not influence anastomotic complications in patients with esophageal cancer treated with neoadjuvant chemoradiation and transhiatal esophagectomy.
    Koëter M; van der Sangen MJ; Hurkmans CW; Luyer MD; Rutten HJ; Nieuwenhuijzen GA
    Radiat Oncol; 2015 Mar; 10():59. PubMed ID: 25884226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer.
    Hamai Y; Hihara J; Emi M; Murakami Y; Kenjo M; Nagata Y; Okada M
    Ann Thorac Surg; 2015 Jun; 99(6):1887-93. PubMed ID: 25912745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction chemoradiotherapy and surgery for esophageal cancer: survival benefit with downstaging.
    Taylor MD; LaPar DJ; Davis JP; Isbell JM; Kozower BD; Lau CL; Jones DR
    Ann Thorac Surg; 2013 Jul; 96(1):225-30: discussion 230-1. PubMed ID: 23618518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer.
    Van Daele E; Scuderi V; Pape E; Van de Putte D; Varin O; Van Nieuwenhove Y; Ceelen W; Troisi R; Pattyn P
    Acta Chir Belg; 2018 Aug; 118(4):227-232. PubMed ID: 29258384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
    Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent.
    Mariette C; Piessen G; Briez N; Triboulet JP
    Ann Surg; 2008 Feb; 247(2):365-71. PubMed ID: 18216546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer.
    Wang J; Suri JS; Allen PK; Liao Z; Komaki R; Ho L; Hofstetter WL; Lin SH
    Am J Clin Oncol; 2016 Jun; 39(3):228-35. PubMed ID: 24710122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of clinical T2N0M0 esophageal cancer.
    Hardacker TJ; Ceppa D; Okereke I; Rieger KM; Jalal SI; LeBlanc JK; DeWitt JM; Kesler KA; Birdas TJ
    Ann Surg Oncol; 2014 Nov; 21(12):3739-43. PubMed ID: 25047477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma.
    Lew JI; Gooding WE; Ribeiro U; Safatle-Ribeiro AV; Posner MC
    Arch Surg; 2001 Jul; 136(7):737-42; discussion 743. PubMed ID: 11448381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
    Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
    Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation.
    Swisher SG; Moughan J; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
    J Thorac Oncol; 2017 Feb; 12(2):368-374. PubMed ID: 27729298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
    Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
    van de Schoot L; Romme EA; van der Sangen MJ; Creemers GJ; van Lijnschoten G; van Driel OJ; Rutten HJ; Nieuwenhuijzen GA
    Ann Surg Oncol; 2008 Jan; 15(1):88-95. PubMed ID: 17896144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of robotic-assisted transhiatal esophagectomy for esophageal cancer after neoadjuvant chemoradiation.
    Coker AM; Barajas-Gamboa JS; Cheverie J; Jacobsen GR; Sandler BJ; Talamini MA; Bouvet M; Horgan S
    J Laparoendosc Adv Surg Tech A; 2014 Feb; 24(2):89-94. PubMed ID: 24401141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.